Combining our first-in-class platform & the science of synthetic genomics to transform RNA therapy.

Chimeron Bio is building a portfolio of self-amplifying RNA therapeutics and vaccines to bring more effective gene therapies and personalized medicines to patients.

Explore Our Pipeline

How we do it

Our ChaESAR Platform

Chimeron Bio’s unique ChaESAR platform leverages chimera encased self-amplifying RNA (saRNA) to achieve superior expression and broader dynamic range compared to other leading messenger RNA (mRNA) technologies.

Learn How

Why we do it

Building on the Modern Science of RNA to Create First-in-Class saRNA Drugs for Patients with Unmet Needs

We are developing a compelling portfolio of innovative and personalized saRNA-based medicines for people with serious diseases including cancer, infectious diseases, and rare genetic disorders, using our technology to achieve superior patient response at a lower dose.

About the Science Explore Our Pipeline

rna cancer infectious disease rare genetic disorders
curve seperator

The Latest from Chimeron Bio

in the news

In the News

March 10, 2021

Chimeron Bio Appoints Dr. Juan José Daboub, Eminent Expert in International Trade and Business Development and Dr. Wilmot James, Distinguished Global Health Policy Scholar to its Accessible Medicines Advisory Board (AMAB)

Philadelphia, PA – Chimeron Bio, an RNA company pioneering a novel class of mRNA-based vaccines and therapeutics, is pleased to announce the appointment of Dr. Juan José Daboub and Dr. Wilmot James to its Accessible Medicines Advisory Board (AMAB). AMAB is established to develop and execute strategies to make Chimeron Bio’s self-amplifying mRNA platform and […]

From Our Blog

July 1, 2020

My Science, My Strongest Tool for Social Justice

The pharma and biotech community can help address not only unmet health needs, but also health inequities. Our role as scientists is critical right now.

passionate about science

Learn more about our COVID-19 Vaccine Program.

See what makes ChaESAR™ a robust anti-viral approach.

Read the Press Release